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ABSTRACT
Objectives To assess structural damage progression
with subcutaneous abatacept (ABA) in the Assessing
Very Early Rheumatoid arthritis Treatment (AVERT) trial
following abrupt withdrawal of all rheumatoid arthritis
(RA) medication in patients achieving Disease Activity
Score (DAS)-deﬁned remission or low disease activity.
Methods Patients with early, active RA were
randomised to ABA plus methotrexate (ABA/MTX)
125 mg/week, ABA 125 mg/week or MTX for
12 months. All RA treatments were withdrawn after
12 months in patients with DAS28 (C reactive protein
(CRP)) <3.2. Adjusted mean changes from baseline in
MRI-based synovitis, osteitis and erosion were calculated
for the intention-to-treat population.
Results 351 patients were randomised and treated:
ABA/MTX (n=119), ABA (n=116) or MTX (n=116).
Synovitis and osteitis improved, and progression of
erosion was statistically less with ABA/MTX versus MTX
at month 12 (−2.35 vs −0.68, −2.58 vs −0.68, 0.19
vs 1.53, respectively; p<0.01 for each) and month 18
(−1.34 vs −0.49 −2.03 vs 0.34, 0.13 vs 2.0,
respectively; p<0.01 for erosion); ABA beneﬁts were
numerically intermediate to those for ABA/MTX and
MTX.
Conclusions Structural beneﬁts with ABA/MTX or ABA
may be maintained 6 months after withdrawal of all
treatments in patients who have achieved remission or
low disease activity.
Trial registration number NCT01142726; Results.
INTRODUCTION
Abatacept is a cytotoxic T lymphocyte-associated
antigen-4 (CTLA-4)–immunoglobulin G1 fusion
protein1 that selectively modulates the CD80/
CD86:CD28 costimulatory pathway required for
T-cell activation.2 In people with rheumatoid arth-
ritis (RA), treatment with abatacept has been shown
to normalise levels of many inﬂammatory mediators
associated with disease activity and progression.1
The Assessing Very Early Rheumatoid arthritis
Treatment (AVERT) trial evaluated clinical remis-
sion at 12 months with subcutaneous abatacept
plus methotrexate (MTX), abatacept monotherapy
or MTX alone in patients with early RA and main-
tenance of remission following rapid withdrawal of
all RA treatments.3 Patients treated with abatacept
in combination with MTX achieved higher rates of
protocol-deﬁned Disease Activity Score (DAS)
remission (DAS28 C reactive protein (CRP) <2.6)
versus MTX alone, and a small but signiﬁcantly
higher number of patients achieved sustained
DAS-deﬁned remission following withdrawal of all
RA treatments.3 The safety proﬁle of abatacept, in
combination with MTX or as monotherapy, was
comparable with that of MTX alone.3
The AVERT trial evaluated clinical and also MRI
outcomes. MRI is increasingly being used in clinical
trials to assess the therapeutic efﬁcacy and can
detect early changes in inﬂammation—including
synovitis, osteitis and joint damage—before radio-
graphic joint erosion occurs;4 in clinical studies,
MRI measures of inﬂammation have even been
shown to predict radiographic progression.5–7 In
patients with established RA, the beneﬁts of abata-
cept in reducing synovitis and osteitis have previ-
ously been demonstrated using MRI.8 9
In this substudy of the AVERT trial, we report
MRI measures of disease in patients with
DAS-deﬁned remission (DAS28 (CRP) <2.6) fol-
lowing 12 months of treatment and subsequent
withdrawal of all RA medication, for up to
18 months.
METHODS
Study design and patient population
The trial design and primary results for AVERT
(NCT01142726) have been described previously.3
Brieﬂy, patients were randomised (1:1:1) to receive
abatacept 125 mg/week plus MTX, abatacept
monotherapy (125 mg/week) or MTX alone for
12 months. At month 12, patients with DAS28
(CRP) <3.2 could enter the withdrawal period and
all treatments for RA were stopped, with MTX and
corticosteroids being tapered during the ﬁrst
month.
Assessments
All patients underwent contrast-enhanced 1.5 T
MRI of the clinically most active wrist and hand
(metacarpophalangeal joints 1–5) at baseline and at
6-month intervals thereafter; the same wrist/hand
was imaged at each designated visit (see online
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supplementary material). MRI assessments were evaluated at
baseline and up to month 18; only patients with baseline and
postbaseline MRI assessments were included (see online supple-
mentary material).
Statistical analysis
Adjusted mean changes from baseline in MRI scores for syno-
vitis, osteitis and erosion were calculated at months 12 and 18
in the intention-to-treat population, and analysed using a longi-
tudinal repeated measures model adjusting for MRI score and
corticosteroid use (yes/no) at baseline and presented by treat-
ment group; observed data at all time points were included. For
all mean response rates, SE, 95% CIs and p values were calcu-
lated (see online supplementary material).
The proportion of patients achieving DAS-deﬁned remission
and MRI non-progression (deﬁned as change from baseline
≤smallest detectable change separately for erosion, osteitis and
synovitis) was calculated at months 6, 12 and 18 as an explora-
tory endpoint (see online supplementary material). The percent-
age change in CRP from baseline was evaluated over time.
Additionally, post hoc analyses included the number of patients
achieving DAS-deﬁned remission and MRI progression (deﬁned
as change from baseline >smallest detectable change) at month
18; the proportion of patients with a synovitis score >5 at base-
line and at months 6, 12 and 18; and adjusted mean changes
from baseline in MRI scores in the subgroup of patients who
had DAS28 (CRP) <2.6 at both months 12 and 18.
RESULTS
Patient disposition and baseline characteristics
A total of 511 patients were enrolled, and 351 patients at 72
worldwide sites were randomly assigned (1:1:1) to treatment
with abatacept plus MTX (n=119), abatacept monotherapy
(n=116) or MTX (n=116). The proportion of patients with
MRI assessments at baseline was 95.8% (114/119), 96.6% (112/
116) and 95.7% (111/116), respectively; at baseline and month
12, it was 76.5% (91/119), 69.8% (81/116) and 72.4% (84/
116), respectively; and at baseline, month 12 and month 18, it
was 31.9% (38/119), 30.2% (35/116) and 25.0% (29/116),
respectively. The average rate of missing MRI scores for those
who had assessments at baseline was 16.9% over 12 months and
69.9% at 18 months. A total of 129/202 patients (63.9%) who
entered the withdrawal period and who had MRI assessments at
baseline and at month 12 discontinued during the withdrawal
period (abatacept plus MTX, n=48 (37.2%); abatacept mono-
therapy, n=40 (31.0%); MTX, n=41 (31.8%)). The main
reason for discontinuation was lack of efﬁcacy (n=123/202;
60.9%). Clinical baseline characteristics for patients with MRI
assessments at baseline and at month 12 were similar across
treatment groups and were comparable with the overall AVERT
population (table 1).
Efﬁcacy
Abatacept plus MTX resulted in signiﬁcantly greater decreases
from baseline in synovitis and osteitis scores on-treatment, and
signiﬁcantly less progression of erosion score on-treatment and
following withdrawal of all therapies than MTX alone (ﬁgure 1).
While mean MRI synovitis and osteitis scores increased following
withdrawal of treatment in all three groups, the adjusted mean
reductions from baseline with abatacept plus MTX at month 18
were still numerically greater than those with MTX alone
(ﬁgure 1A, B). Changes in erosion score showed minimal differ-
ence between months 6 and 18 (ﬁgure 1C). Beneﬁts of abatacept
monotherapy were numerically intermediate to those of
abatacept plus MTX and MTX alone. Cumulative probability
plots for changes in MRI scores from baseline at month 12 are
shown in online supplementary ﬁgure S1.
During study treatment, there was a reduction in the propor-
tion of patients with active synovitis (score >5; indicative of
active disease resulting in erosion progression10) in the abatacept
plus MTX group versus that in the MTX alone group; at month
18, there was a numerical increase versus MTX alone (see
online supplementary ﬁgure S1).
During study treatment, a statistically higher percentage of
patients receiving abatacept plus MTX achieved DAS-deﬁned
remission together with MRI non-progression in synovitis, oste-
itis and erosion compared with those receiving MTX alone
(table 2). Fewer patients in all three treatment groups achieved
DAS-deﬁned remission together with MRI non-progression after
withdrawal of study drug compared with on-treatment (table 2).
However, the percentages of patients in the abatacept plus
MTX group were still approximately twice those of the
MTX-alone group. The effect of abatacept monotherapy was
numerically intermediate to that of abatacept plus MTX and
MTX alone. In all treatment groups, a small number of patients
still had MRI progression (see online supplementary material).
Post hoc analyses revealed that, in the small proportion of
patients with DAS-deﬁned remission at both months 12 and 18,
MRI beneﬁts achieved at month 12 were maintained up to
month 18 (ie, after withdrawal of all therapies) in all three
groups (see online supplementary ﬁgure S3).
Abatacept plus MTX treatment resulted in greater decreases
from baseline in the inﬂammatory marker, CRP, during the treat-
ment period and following the withdrawal of all therapies com-
pared with MTX alone. Abatacept monotherapy and MTX
alone had similar effects on CRP (see online supplementary
table S1).
DISCUSSION
In this analysis of tissue effects, abatacept reduced inﬂammation
and structural damage progression as assessed by changes in
MRI scores (synovitis, osteitis and bone erosions) in patients
with early and progressive RA. Following withdrawal of all ther-
apies in patients with clinical disease activity, there was some
reappearance of inﬂammatory activity in the joints. However, in
those patients who maintained clinical remission or low disease
Table 1 Baseline characteristics for patients with MRI assessments
at baseline and month 12
Characteristic
Abatacept plus
MTX (n=91)
Abatacept
monotherapy (n=81)
MTX
(n=84)
Synovitis score 5.6 (4.2) 5.3 (3.8) 5.7 (4.2)
Osteitis score 4.4 (6.9) 4.3 (6.7) 3.4 (6.4)
Erosion score 7.2 (7.0) 5.1 (4.7) 6.3 (7.8)
Symptom duration,
years
0.6 (0.5) 0.6 (0.5) 0.5 (0.5)
DAS28 (CRP) 5.5 (1.3) 5.5 (1.2) 5.3 (1.3)
HAQ-DI 1.5 (0.7) 1.4 (0.6) 1.4 (0.6)
Tender Joint Count
(28 joints)
13.8 (7.8) 14.3 (7.7) 12.5 (7.7)
Swollen Joint Count
(28 joints)
11.2 (7.1) 12.4 (7.6) 10.2 (6.9)
CRP, mg/L 17.5 (23.2) 16.6 (25.6) 16.0 (21.2)
Data are presented as mean (SD).
CRP, C reactive protein; DAS, Disease Activity Score; HAQ-DI, Health Assessment
Questionnaire-Disability Index; MTX, methotrexate.
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activity following withdrawal of all RA therapy, this remission/
low disease activity correlated with maintenance of inﬂamma-
tion control and structural beneﬁts irrespective of initial treat-
ment group. During both the treatment and withdrawal periods,
improvements as assessed by MRI were greatest for abatacept
plus MTX, followed by abatacept monotherapy and MTX
monotherapy.
The improvements in MRI scores observed in the present study
are consistent with previous abatacept studies9 11 and recent ran-
domised controlled trials of other biologics in patients with early
or established RA (see online supplementary material).12–16 The
data presented here are also consistent with the maintenance of
MRI beneﬁts for 6 months following the withdrawal of abatacept
in patients with early RA reported in the ADJUST trial.9 Only a
few studies of biologics have evaluated treatment withdrawal or
de-escalation and imaging outcomes (MRI or radiography) in
patients with RA.17–20 Consistent with our study, Smolen et al
showed that most patients with early RA (<1 year disease dur-
ation) who achieved a stable low-dose disease activity target at
∼6 months maintained structural beneﬁts, despite withdrawal of
adalimumab. Similarly, induction treatment with MTX plus adali-
mumab was shown to result in fewer erosions at 1 year versus
Figure 1 Adjusted mean change from baseline in MRI scores (ITT population). Change from baseline in (A) synovitis scores, (B) osteitis and
(C) erosion at 6, 12 and 18 months. *p<0.05, **p<0.01 and ***p<0.001 for adjusted mean difference versus MTX at given time point. Error bars
represent SEs. ITT, intention-to-treat; MTX, methotrexate.
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MTX alone in patients who discontinued adalimumab after
6 months’ treatment.17–20
Some limitations of the present study should be taken into
account. The post hoc analysis of change from baseline in MRI
scores in patients with DAS28 (CRP) <2.6 at both months 12
and 18 had a small sample size, and therefore additional studies
are needed to conﬁrm these results, despite the sensitivity of
MRI for detecting change. Additionally, the study was not
powered to compare abatacept combination therapy with
monotherapy.
In conclusion, these data from the AVERT study demonstrate
that abatacept reduces inﬂammation and structural damage pro-
gression as assessed by MRI, and extends the current under-
standing of the effect of abatacept on synovium and bone. The
withdrawal of abatacept therapy after achieving remission in
some patients with early, progressive RA appears to be possible
without an associated risk of joint damage progression.
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Table 2 Proportion of patients with DAS28 (CRP) remission and MRI non-progression per MRI pathology over time (ITT population)
Patients with DAS28 (CRP) remission* and MRI
non-progression†
MRI pathology
Study time
point
(months)
Abatacept plus
MTX (n=119)
Abatacept
monotherapy
(n=116) MTX (n=116)
Abatacept plus MTX vs
MTX estimate of
difference
(95% CI)
Abatacept monotherapy vs
MTX estimate of
difference
(95% CI)
Synovitis—n‡ (%)
(95% CI)§
6 44 (37.0)
(28.30 to 45.65)
32 (27.6)
(19.45 to 35.72)
28 (24.1)
(16.35 to 31.93)
12.84 (0.33 to 25.34);
p=0.046
3.45 (−8.67 to 15.57);
p=0.653
12 59 (49.6)
(40.60 to 58.56)
43 (37.1)
(28.28 to 45.86)
41 (35.3)
(26.65 to 44.04)
14.24 (0.88 to 27.59);
p=0.038
1.72 (−11.50 to 14.95);
p=0.891
18 18 (15.1)
(8.69 to 21.56)
11 (9.5)
(4.15 to 14.81)
9 (7.8)
(2.89 to 12.63)
7.37 (−1.55 to 16.29);
p=0.117
1.72 (−6.36 to 9.81);
p=0.815
Osteitis—n‡ (%)
(95% CI)§
6 43 (36.1)
(27.50 to 44.77)
32 (27.6)
(19.45 to 35.72)
27 (23.3)
(15.6 to 30.97)
12.86 (0.45 to 25.27);
p=0.044
4.31 (−7.75 to 16.37);
p=0.546
12 58 (48.7)
(36.76 to 57.72)
42 (36.2)
(27.46 to 44.95)
41 (35.3)
(26.65 to 44.04)
13.39 (0.04 to 26.75);
p=0.052
0.86 (−12.34 to 14.06);
p=1.000
18 18 (15.1)
(8.69 to 21.56)
12 (10.3)
(4.80 to 15.89)
9 (7.8)
(2.89 to 12.63)
7.37 (−1.55 to 16.29);
p=0.117
2.59 (−5.65 to 10.82);
0.647
Erosion—n‡ (%)
(95% CI)§
6 38 (31.9)
(23.56 to 40.31)
30 (25.9)
(17.89 to 33.83)
23 (19.8)
(12.57 to 27.08)
12.11 (0.17 to 24.04);
p=0.049
6.03 (−5.60 to 17.67);
p=0.348
12 51 (42.9)
(33.97 to 51.75)
36 (31.0)
(22.62 to 39.45)
33 (28.4)
(20.24 to 36.66)
14.41 (1.46 to 27.36);
p=0.030
2.59 (−10.04 to 15.21);
p=0.774
18 15 (12.6)
(6.64 to 18.57)
11 (9.5)
(4.15 to 14.81)
8 (6.9)
(2.29 to 11.51)
5.71 (−2.68 to 14.10);
p=0.210
2.59 (−5.32 to 10.50);
p=0.632
*DAS-defined remission was defined as DAS28 (CRP) <2.6.
†MRI non-progression was defined as change from baseline ≤smallest detectable change. Smallest detectable change values used for non-progression: synovitis (2.01), osteitis (2.81) and
erosion (2.29).
‡n=number of patients with DAS28 (CRP) remission and MRI non-progression.
§Normal approximation is used if the number of DAS28 (CRP) remission and MRI non-progression for all treatment arms was at least 5; otherwise an exact method was used.
CRP, C reactive protein; DAS, Disease Activity Score; ITT, intention-to-treat; MTX, methotrexate.
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